Seminars in Nephrology
Volume 27, Issue 2 , Pages 144-152, March 2007

The Renin-Angiotensin System and Diabetic Nephropathy

  • Susan B. Gurley, MD, PhD
  • ,
  • Thomas M. Coffman, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Thomas M. Coffman, MD, Building 6/Nephrology (111I), VA Medical Center, 508 Fulton St, Durham, NC 27705.

Division of Nephrology, Department of Medicine, Duke University and Durham VA Medical Centers, Durham, NC

Summary 

The renin-angiotensin system (RAS) has key regulatory functions for blood pressure and fluid homeostasis. In addition, dysregulation of the system can have maladaptive effects to promote tissue injury in chronic diseases such as hypertension, heart failure, and kidney disease. These actions for the RAS to promote disease pathogenesis are especially apparent in diabetic nephropathy, the most common cause of end-stage renal disease in the United States. Evidence of a role for the RAS in diabetic nephropathy comes from studies in animal models and randomized clinical trials showing efficacy of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers to slow the progression of renal disease. Widespread applications of these therapies to a range of renal diseases may have contributed to the recent reduction in the incidence rates for end-stage renal disease. We provide a general review of the RAS and its role in diabetic nephropathy.

Keywords: Renin-angiotensin system, angiotensin II, ACE inhibitor, angiotensin receptor blocker

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by grants from the National Institutes of Health (5 U01 HL070523-05), the American Heart Association, and the US Department of Veterans Affairs.

PII: S0270-9295(07)00010-1

doi:10.1016/j.semnephrol.2007.01.009

Seminars in Nephrology
Volume 27, Issue 2 , Pages 144-152, March 2007